David I. Quinn, MD, explains discusses Keynote 427 for Pembrolizumab, PD-1 Inhibitor and CTLA4 with Nivolumab & Ipilimumab presented at the 2018 Annual Meeting Annual Meeting.
Thoughts on Keynote 427 – Single Agent Pembrolizumab
David I. Quinn, MD, explains discusses Keynote 427 for Pembrolizumab, PD-1 Inhibitor and CTLA4 with Nivolumab & Ipilimumab presented at the 2018 Annual Meeting Annual Meeting.